Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus anlotinib for primary hepatocellular carcinoma with lung metastasis
ChiCTR2200056221Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Primary endpoint: Time to progression. Started Mar 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200056221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056221.